Австралия - английский - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - insulin glargine, quantity: 100 u/ml - injection, solution - excipient ingredients: sodium hydroxide; glycerol; water for injections; hydrochloric acid; metacresol; zinc chloride - insulin glargine is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia.

Соединенные Штаты - английский - NLM (National Library of Medicine)

defyaging.com inc. - phosphoric acid (unii: e4ga8884nn) (phosphoric acid - unii:e4ga8884nn), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f), somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl), mecasermin (unii: 7gr9i2683o) (mecasermin - unii:7gr9i2683o), sus scrofa pituitary gland (unii: e8s87o660t) (sus scrofa pituitary gland - unii:e8s87o660t) - indications: clinical studies suggest the following types of symptom relief associated with aging: poor muscle/fat balance, low stamina and energy, decrease in sexual function, sleeplessness, weak immune system, irritability, poor memory, dry wrinkled skin. indications:  clinical studies suggest the following types of symptom relief associated with aging: poor muscle/fat balance, low stamina and energy, decrease in sexual function, sleeplessness, weak immune system, irritability, poor memory, dry wrinkled skin.

Соединенные Штаты - английский - NLM (National Library of Medicine)

problen - choline alfoscerate (unii: 60m22sgw66) (choline alfoscerate - unii:60m22sgw66), cervus elaphus velvet (unii: z608183yd0) (cervus elaphus velvet - unii:z608183yd0), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f), somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl), long-(arg3)insulin-like growth factor-i (unii: m9l22y19h9) (long-(arg3)insulin-like growth factor-i - unii:m9l22y19h9), insulin-like growth factor-2 (unii: 95067d43fq) (insulin-like growth factor-2 - unii:95067d43fq), sus sc - ​indications: ​temporarily supports the body to rebalance human growth hormone (hgh) output. symptoms of imbalanced hgh may include: poor muscle/fat balance, dry wrinkled-looking skin, low energy, sleeplessness, weak immune system. ​these statements have not been evaluated by the food and drug administration. this product is not intended to diagnose, treat, cure or prevent any disease.

Соединенные Штаты - английский - NLM (National Library of Medicine)

guna spa - mecasermin (unii: 7gr9i2683o) (mecasermin - unii:7gr9i2683o) - neuroendocrine support neuroendocrine support

Израиль - английский - Ministry of Health

novartis israel ltd - somatropin recombinant - solution for injection - somatropin recombinant 10 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

Израиль - английский - Ministry of Health

novartis israel ltd - somatropin recombinant - solution for injection - somatropin recombinant 15 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

Израиль - английский - Ministry of Health

masrouji co, ltd - somatropin recombinant - solution for injection - somatropin recombinant 5 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

Израиль - английский - Ministry of Health

medison pharma ltd - mecasermin - solution for injection - mecasermin 10 mg / 1 ml - mecasermin - for the long-term treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (primary igfd).severe primary igfd is defined by:* height standard deviation score ≤–3.0and* basal igf-1 levels below the 2.5th percentile for age and genderand* gh sufficiency.* exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signaling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment.in some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an igf-i generation test.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - octreotide, quantity: 30 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.